The present invention is directed to functional gums, suckers (e.g., lollipops) and lozenges, and more particularly, to a gum and/or sucker and/or lozenge that has at least an exterior and an interior component, having distinct metabolic and functional characteristics that correspond with the ingredients contained therein.
Throughout the ages, human beings have attempted to attain and maintain particular body morphologies, and in particular, have attempted to control their weight so as to conform with then-fashionable mores. During the recent past, a preference for less massive morphologies has been in vogue and a populous genetically ill-equipped to conform with such weight characteristics is bombarded with images of svelte figures in both male and female forms.
The desire of individuals to lose weight and specifically, to lose fatty tissue, has become nearly an obsession in the United States and many other countries. Any simple and safe method toward achieving a slim figure is in great demand. Methods for losing weight include hundreds of advised diets, machines and methods for exercise, various psychiatric techniques involving alteration in mental attitudes, and a variety of surgical techniques. Liposuction has created an entirely new surgical cosmetic industry, but carries a small but significant risk and often leaves the patient with an unsightly cosmetic result due to the inflammatory reaction surrounding where the fatty tissue has been removed by a technique which produces a severe tissue reaction.
Obesity is a serious public health hazard, second in importance only to tobacco. Approximately ⅓ of Americans are seriously overweight according to life insurance data. In approximately 12 million Americans, obesity significantly contributes toward the cause and complications of serious disease. Such conditions include heart and lung disease, many types of cancer, diabetes, high blood pressure, and peripheral arterial disease. This is in addition to how obesity becomes a cosmetic problem. Being overly fat limits both length of life and its quality.
A multi-billion dollar industry has developed in an effort to control weight. The many varied and expensive techniques employed speak to the relative ineffectiveness of the many techniques that have been tried to get rid of excess fat.
Obesity has recently been recognized as a public health hazard of epidemic proportions by the World Health Organization. One of three Americans between the ages of 20-74 are obese (Body Mass Index>30 Kg/m2 body surface). This amounts to 58 million people. The number of obese adults has increased dramatically. In 1980 25% of US adults were obese. The equivalent figure was 33% in 1990. In Europe the equivalent figure is about 40%.
Obesity significantly contributes to the dangers of other diseases in approximately half of those who exceed the threshold description of obesity. For example, 19% of the cost of management of heart disease can be ascribed to obesity. Obesity is also recognized as a co-morbid factor for obese patients suffering from degenerative arthritis, peripheral vascular disease, and many forms of pulmonary disease such as emphysema. The expenditure for products, goods, and services in the management of obesity is estimated to be $33 billion per year. This is 3%-4% of total health care expenditure per year and exceeds that expended for AIDS and cancer.
Obesity is such a prevalent, important and distressing problem that its many methods for suggested management are too well known to deserve more than listing. They include diets that exclude fats and high caloric elements, food supplements, appetite suppressants, exercise machines and regimes, biofeedback and other psychotherapeutic techniques, and a variety of operative techniques. Operations include a number of methods for decreasing the capacity the stomach, gastric by-pass operations, methods to shorten the small intestinal absorption surface, excision of the unwanted fat (lipectomy) and techniques of liposuction. Liposuction is performed approximately 51,000 times each year in the US. The maximum amount of fat that can safely be removed is approximately 2 Kg. Being an operative technique for removing fat, in this case by suction, it inevitably excites an inflammatory response at the operative site, which results not only in post operative inflammation but in subsequent uneven and unsightly scarring beneath the skin where the fat has been removed.
Incorporated by reference in its entirety are the following U.S. patents directed generally to chewing gum compositions, methods and apparatus for making chewing gum, and in particular, methods for enabling one of skill in the art to produce soft-centered chewing gums as contemplated by the present invention. The novelty of the present invention, however, should be understood as being distinguished from such prior art references and such incorporation by reference is only provided for enabling support of the numerous ways in which the particular novel product can be manufactured. The U.S. patents incorporated by reference are as follows: U.S. Pat. Nos. 5,922,347; 5,916,606; 5,912,030; 5,900,230; 5,885,630; 5,866,179; 5,858,423; 5,846,557; 5,834,002; 5,827,526; 5,824,291; 5,736,175; 4,156,740; 5,498,429; 4,466,983; 4,157,402; 5,569,477; 5,125,819; 5,248,508; 4,975,288; 4,792,453; 4,980,178; 4,683,138; 5,087,460; 4,292,329; 4,642,235; 4,316,915; 4,513,012; 4,250,196; 5,431,929; and 4,647,450.
Weight control systems and methods have improved over the years. Indeed, the ancient Romans believed that the vomitorium was penance for their uncontrollable feasting and drinking during long celebrations for their various deities. Modern methods of weight control including arduous and sometimes bizarre workout routines and machines are no less peculiar in modern times. Moreover, with the advent of liposuction, stomach stapling, etc., there appears to be no bounds beyond which humans will go to attain desired physical characteristics as such relate to their weight. The effect of such weight norms has created a $60 billion a year market for diet and weight control products. It is estimated that nearly half of all American women, and a quarter of all men, are on a diet at any given time. As is well known, however, most diets, studies have shown, do not work for nine out of ten people who, after suffering through such diets, quickly regain their weight and often exceed their previous body mass. Such an unfortunate volley of feasting and dieting leads not only to physical harm due to increased rates of diabetes, arterial sclerosis, and other physical health problems, but also to an often devastating decreased estimation of a person's self-worth.
There is thus a long felt but unsolved need for an effective, inexpensive and easy way in which to provide health conscious individuals with diet products to assist in achieving desired weight loss.
In one embodiment, the present invention is directed to a method and product which provides functional components such as, herbal, medicinal and/or vitamin substances for various applications (e.g., weight control substances) to an individual other than through the consumption of pills, suppositories, diet beverages and/or tasteless and low caloric foodstuffs. In one embodiment, the present invention is directed to a particular gum product having at its center a composition different from the surrounding gum and having distinct functional and metabolic characteristics. For example, various metabolism increasing components can be provided in the interior of a gum in a liquid or semi-liquid form while the gum itself can be of a traditional gum composition and/or may incorporate various other desirable metabolic increasing components to supplement and/or coact with components contained in the liquid center of the gum. Indeed, in one particular embodiment of the present invention, time release capsules may be provided suspended in a liquid medium inside a gum enclosure.
The present discussion pertains principally to a diet control gum/lozenge/lollipop, but the present invention is not so limited and includes one or more combinations of ingredients as set forth, for example, in Tables I and II below, which may be useful in numerous and varied applications. For illustration purposes only, however, the following discusses weight loss applications of the present invention. In one embodiment, chewing of the gum-based product releases the interior liquid substance, thus providing a product and a method desirable by weight conscious individuals who do not wish to publicly announce or disclose their dietary desires. In a preferred embodiment, the substance contained within the gum (e.g. the interior liquid substance) would have as a principal characteristic the capability of increasing a user's caloric burn rate (e.g. by increasing a person's metabolism, adjusting/regulating hormonal activity in an individual, providing fiber to increase a person's feelings of satiety).
In a particular embodiment of the present invention, a gum is utilized having liquid interior components surrounded by the dense gum, for example, the interior having a density less than 10% as dense as the exterior gum, more preferably at least about 15% less dense, and more preferably, at least about 35% less dense than the surrounding gum. The interior liquid components can be herbal, organic, natural, chemical and/or hormonal in nature, and may be selected dependent upon their individual and synergistic characteristics, with the objective being to increase a person's metabolism in order to achieve a higher caloric burn rate and/or to decrease the desire for additional food (e.g. generate a feeling of satiety or fullness). It is within the scope of the present invention to incorporate various known diet control substances in either the gum material itself and/or in the liquid interior material encompassed by the gum material. In a preferred embodiment, however, the surrounding gum material is comprised of traditional gum flavors and compositions and the interior liquid and/or semi-liquid (e.g. gel) components of the present invention comprise diet regulating substances.
Yet another embodiment of the present invention relates to a hard candy substance (e.g. primarily comprising a natural sugar and corn syrup base) often referred to as a “sucker” or “lollipop.” The interior of the sucker or lollipop, however, contains a less rigid, soft and/or liquid or semi-liquid component. The enclosed material of the lollipop includes metabolic enhancers for weight and caloric control.
In still another embodiment, a lozenge can be manufactured having a denser exterior and a less dense interior, where either the interior or exterior of the lozenge, or both, contain diet controlling substances. Preferably, diet controlling substances are positioned within the interior of such lozenges so as to facilitate the enjoyment by an individual of consuming the lozenge without the possible unpleasant and/or undesirable taste characteristics of various dietary components within the center of the lozenge.
It will be understood that one purpose of certain embodiments of the present invention is to increase metabolic efficiency and to burn calories in an individual. Herbal additives may be incorporated into such products to aid in the body's ability to digest food and/or to block absorption of fat molecules into the system. For example, chitosan compositions can be utilized either in the interior and/or exterior of the gum, lollipop and lozenge embodiments desired above and hereafter. In addition to chitosan, other fiber-like components, vitamins and minerals (e.g., especially calcium compositions to treat osteoporosis) can be incorporated into the present invention to provide desired feelings of satiety or fullness to an individual using such products and/or to treat various vitamin and/or mineral deficiencies.
While the present invention is primarily directed to administering diet control substances to individuals, it should be understood that other medicinal and/or nutritional and/or biological components can be administered to animals in general (companion pets, livestock, etc.) but preferably humans. Indeed, the present inventor believes that the administration of medicinal compounds to young children can be greatly facilitated by use of the present invention given that children are more apt to take medicine in the form of a lollipop, lozenge or gum, particularly if the taste and flavor and textural characteristics of such candy products are preserved and effective amounts of desired components are delivered to such individuals when consuming such products.
Muscle atrophy, or wasting, is caused by aging and a variety of illnesses and injuries, including cancer, heart failure, and orthopedic injuries. It makes people weak and fatigued, impairs physical activity and quality of life, and predisposes people to falls and fractures. The condition affects more than 50 million Americans annually, including 30 million people over age 60, and often forces people into nursing homes or rehabilitation facilities. Skeletal muscle atrophy is a common and debilitating condition that lacks an effective therapy. Although skeletal muscle atrophy has broad clinical impact, current treatment recommendations (e.g. physical rehabilitation, nutritional optimization, and treatment of underlying disease) are often ineffective and/or unfeasible. Moreover, a pharmacologic therapy does not exist. Thus, skeletal muscle atrophy represents a very large unmet medical need.
A natural small molecule from tomato plants, tomatidine, is believed to cause cell growth, especially in skeletal muscle tissue. Properly administered, such as via the methods and systems set forth herein, tomatidine is an effective agent to treat muscle atrophy and to further increase strength and exercise capacity. Tomatidine is an inhibitor of muscle atrophy and thus has a use as a therapeutic agent for skeletal muscle atrophy. Tomatidine is a steroidal alkaloid and the aglycone of α-tomatine, an abundant glycoalkaloid in tomato plants that mediates plant defense against fungi, bacteria, viruses and predatory insects. When consumed by animals, α-tomatine is hydrolyzed by stomach acid and intestinal bacteria to tomatidine, which is absorbed by the gut. Tomatidine's effects on skeletal muscle are unknown. However, the finding that the mRNA expression signature of tomatidine negatively correlated to signatures of muscle atrophy suggest that tomatidine has an anti-atrophic (anabolic) effect in skeletal muscle.
In one embodiment, a person having from one, preferably two, and more preferably three pieces of center-filled chewing gum in a 24 hour period of time, such gum containing tomatidine, is able to achieve the stimulation of skeletal muscle anabolism, leading to muscle hypertrophy, increased strength and improved exercise capacity. In still other embodiments, especially those including one or more of the agents as set forth in Tables I and II, and especially at least one metabolic enhancer, tomatidine provided in at least a 1 mg per piece of gum, is believed to result in two major effects on body composition, namely, increased skeletal muscle and decreased fat. Tomatidine is believed to limit the progression of skeletal muscle atrophy during fasting and muscle disuse, and enhances the recovery from disuse skeletal muscle atrophy. Tomatidine and/or α-tomatine are also important components in various embodiments of the present invention directed to inclusion into so-called functional foods and nutraceuticals designed to maintain muscle mass and function in persons without muscle atrophy. In addition to having potential utility in its own right, tomatidine supports the concept that systems-based methods can be used to discover small molecules that improve skeletal muscle mass, function and metabolism. Such compounds could potentially have several beneficial uses for patients and society in general.
Studies have shown that tomatidine fed mice had larger muscles, but their overall body weight did not change due to a corresponding loss of fat. Thus, another aspect of the present invention directed to treating obesity, is further enhanced by providing certain amounts of tomatidine as an effective compound in the treatment of obesity. Tomatidine is a natural compound derived from tomatoes and is produced when alpha-tomatine, which is found in green tomatoes, is digested in the gut. Tomatidine is significantly more potent than ursolic acid in building muscle tissue and has a different mechanism of action. One application of the present invention is to provide a center-filled chewing gum lollipop or lozenge that contains tomatidine, as well as other select agents (set forth herein) in a manner that is effective to preserve muscle mass and function during the aging process. Preferably, the compositions included in the gum center-fill or in the gum base material contain tomatidine without any ursolic acid.
As set forth in Tables I and II below, certain embodiments of the present invention are directed to a center-filled gum, lozenge or lollipop that includes particular combinations of active ingredients, including calcium, vitamin E and a chemotherapeutic agent and/or Herbal component, which in certain embodiments consists of tomatidine. Incorporated herein by this reference are the following US patent publications, which further demonstrate that tomatidine falls into such classifications set forth in Tables I and II herein, i.e. US Patent Publication Nos. 20140030332 to Baron, et. al., and 20070123448 to Kaplan et al.
The following table contains a list of possible components that may be incorporated into the center of the gum, lollipop and lozenge aspects of the present invention:
The following U.S. issued patents are also incorporated herein by reference: U.S. Pat. No. 5,474,989 by Hasimoto et al., U.S. Pat. No. 5,747,475 by Norquist et al., U.S. Pat. No. 5,830,883 by Block et al., U.S. Pat. No. 5,880,109 by Nakamura et al., U.S. Pat. No. 4,963,367 by Ecanow, U.S. Pat. No. 4,738,850 by Thakur et al., U.S. Pat. No. 5,846,952 by Vournakis et al., and U.S. Pat. No. 4,223,023 by Furda. It will therefore be appreciated by one of skill in the art that various compositions, formulations, masking agents (e.g., to “mask” unpleasant flavors and/or textures and/or mouth feel characteristics of vitamins, medicinal compounds, minerals, etc.) and binders can be combined with the present structure of the present invention to achieve various desired purposes. For example, controlled release formulations are encompassed by the present invention as are the preparation and use of various different carrier vehicles useful for medicinally administering compositions to animals, time release formulations, compositions having desirable solubility and dissolution rates, and the incorporation into the present invention of food additives such as vitamins, pharmaceutical preparations and other compounds, specifically those that reduce the absorption of lipids such a chitosan.
Both the gum with liquid-type fillers and the sucker with a gum-based center can be comprised of one or more of the following: xanthan, guar, locust bean gum, karaya, gum tragacanth, carrageenans, alginates, gum arabic, corn syrup, sugar, starches, gum bases. While multiple recipes exist, most candy substances can also be made from natural and herbal substitutes listed in Table II. The cavities that are extruded in both the gum and the lollipop can be made with one or more cavities that can be filled with multiple bio-enhancing and weight management substances, compiling all or some of the properties in Table II. The combination of them will achieve various results. Example: Guarana and malluang and chitosan will create energy and a feeling of “fullness” for the consumer; chromium picolinate (RE. 33, 988) and ginseng and ginger will allow the user to burn calories more efficiently).
Astragalus
Gymnema Sylvestre
The amounts of all or some of these ingredients can vary, preferably being present in an amount between no less than about 0.05 mg. The size of the gum exterior can be made of a size less than 4.5 grams to more than 18.4 grams with the cavity center being able to accommodate a volume between 0.5 mg to more than 5 grams. The lollipop can be a total size of less than 0.65 oz. with the cavity center being a volume of no more than 0.42 oz. and no less than 4.5 grams, to a size larger than 1.35 oz. with a cavity center being of at least 19 grams.
In one particular embodiment, the invention is directed to a beverage, so-called a Bloody Mary beverage, that includes the following: in a 12 fluid once serving: up to but not exceeding 9.9% alcohol (by volume); no fat; up to 1200 mg of sodium; 3 grams of protein; Vitamin C, Vitamin A, calcium, potassium and iron. In a preferred embodiment the beverage includes water, tomato concentrate, natural grain spirits, high fructose corn syrup, aloe vera juice, sodium chloride, vinegar, citric acid, taurine, pectin, ascorbic acid, and citrus aurantium extract. In still other embodiments, the beverage includes the following: fresh horseradish, tomato juice, Tabasco, Worcestershire sauce, celery salt, and one of amontillado; cream sherry, and pure cane sugar. In yet another embodiment, the present invention includes a beverage consisting of: water; a tomato concentrate having a tomato soluble solids content of about 24% to about 36% by weight, ethyl alcohol, Vitamin C, Vitamin A, calcium, potassium, iron, water, high fructose corn syrup, aloe vera juice, sodium chloride, vinegar, citric acid, taurine, pectin, ascorbic acid, and citrus aurantium extract, horseradish, Worcestershire sauce, and celery salt. Certain other embodiments are directed to a Bloody Mary beverage that has the benefits of an energy drink, and include at least the following: tomato juice containing lycopene, Ginger, Honey, taurine and caffeine. By way of providing additional background, context, and to further satisfy the written description requirements of 35 U.S.C. §112, the following references are incorporated by reference in their entireties: U.S. Patent Publication No. 20130115329 to Savant, et al. and U.S. Pat. No. 8,202,561 to Livaich. One of skill in the art will further appreciate that the beverage ingredients of the above can also be incorporated into the chewing gum and lollipop embodiments as further described herein.
While various embodiments of the present invention have been described in detail, it is apparent that further modifications and adaptations of the invention will occur to those skilled in the art. However, it is to be expressly understood that such modifications and adaptations are within the spirit and scope of the present invention.
This is a continuation-in-part application of pending prior application Ser. No. 14/220,224 filed on Mar. 20, 2014, which is a continuation-in-part of application Ser. No. 12/052,054 filed on Mar. 20, 2008 (now U.S. Pat. No. 8,679,522), which is a continuation of application Ser. No. 11/084,707 filed on Mar. 17, 2005 (now U.S. Pat. No. 7,351,425), which is a continuation of prior application Ser. No. 10/646,503 filed on Aug. 21, 2003 (now U.S. Pat. No. 6,869,614), which is a continuation of application Ser. No. 10/316,700 filed on Dec. 10, 2002 (now U.S. Pat. No. 6,652,839), which is a continuation of application Ser. No. 09/664,630 filed on Sep. 19, 2000 (now U.S. Pat. No. 6,491,540) and claims priority from U.S. Provisional Patent Application No. 60/154,972 filed on Sep. 20, 1999. The entire disclosure of the prior applications are considered to be part of the disclosure of the accompanying application and are hereby incorporated by reference.
Number | Name | Date | Kind |
---|---|---|---|
1298670 | Cramer | Apr 1919 | A |
1629461 | Berg et al. | May 1927 | A |
2892753 | Schmidt et al. | Jun 1959 | A |
2990328 | Lincoln | Jun 1961 | A |
3011949 | Bilotti | Dec 1961 | A |
3029189 | Hardy, Jr. et al. | Apr 1962 | A |
3047461 | Hardy, Jr. et al. | Jul 1962 | A |
3075884 | Bilotti et al. | Jan 1963 | A |
3196172 | Wright, Jr. et al. | Jul 1965 | A |
3308022 | Cummings et al. | Mar 1967 | A |
3498964 | Hayashi et al. | Mar 1970 | A |
3554767 | Daum et al. | Jan 1971 | A |
3590057 | Suzuki et al. | Jun 1971 | A |
3845217 | Ferno et al. | Oct 1974 | A |
3877468 | Lichtneckert et al. | Apr 1975 | A |
3894154 | Graff et al. | Jul 1975 | A |
3901248 | Lichtneckert et al. | Aug 1975 | A |
3995064 | Ehrgott et al. | Nov 1976 | A |
4150161 | Rudolph et al. | Apr 1979 | A |
4154814 | Hand et al. | May 1979 | A |
4156740 | Glass et al. | May 1979 | A |
4157402 | Ogawa et al. | Jun 1979 | A |
4223023 | Furda | Sep 1980 | A |
4238475 | Witzel et al. | Dec 1980 | A |
4238510 | Cherukuri et al. | Dec 1980 | A |
4250195 | Cherukuri et al. | Feb 1981 | A |
4250196 | Friello | Feb 1981 | A |
4283408 | Hirata et al. | Aug 1981 | A |
4292329 | Ogawa et al. | Sep 1981 | A |
4316915 | Friello et al. | Feb 1982 | A |
4317838 | Cherukuri et al. | Mar 1982 | A |
4372942 | Cimiluca | Feb 1983 | A |
4374858 | Glass et al. | Feb 1983 | A |
4378374 | Reggio et al. | Mar 1983 | A |
4386063 | Boden | May 1983 | A |
4386106 | Merritt et al. | May 1983 | A |
4400372 | Muhler et al. | Aug 1983 | A |
4446135 | Fountaine | May 1984 | A |
4452821 | Gergely | Jun 1984 | A |
4459311 | DeTora et al. | Jul 1984 | A |
4466983 | Cifrese et al. | Aug 1984 | A |
4474749 | Kruppa | Oct 1984 | A |
4496592 | Kuwahara et al. | Jan 1985 | A |
4512968 | Komiyama et al. | Apr 1985 | A |
4513012 | Carroll et al. | Apr 1985 | A |
4533556 | Piccolo et al. | Aug 1985 | A |
4555407 | Kramer et al. | Nov 1985 | A |
4563345 | Arrick | Jan 1986 | A |
4639368 | Niazi et al. | Jan 1987 | A |
4642235 | Reed et al. | Feb 1987 | A |
4647450 | Peters et al. | Mar 1987 | A |
4683138 | Glass et al. | Jul 1987 | A |
4711774 | Denick, Jr. et al. | Dec 1987 | A |
4716033 | Denick, Jr. | Dec 1987 | A |
4737366 | Gergely et al. | Apr 1988 | A |
4738850 | Thakur et al. | Apr 1988 | A |
4753800 | Mozda | Jun 1988 | A |
4753805 | Cherukuri et al. | Jun 1988 | A |
4755389 | Jones et al. | Jul 1988 | A |
4758424 | Denick, Jr. et al. | Jul 1988 | A |
4792453 | Reed et al. | Dec 1988 | A |
4822597 | Faust et al. | Apr 1989 | A |
4822816 | Markham | Apr 1989 | A |
4828820 | Glass et al. | May 1989 | A |
4832994 | Fey | May 1989 | A |
4835162 | Abood | May 1989 | A |
4849227 | Cho | Jul 1989 | A |
4853212 | Faust et al. | Aug 1989 | A |
4867989 | Silva et al. | Sep 1989 | A |
4882152 | Yang et al. | Nov 1989 | A |
4894234 | Sharma et al. | Jan 1990 | A |
4908211 | Paz | Mar 1990 | A |
4908212 | Kwon et al. | Mar 1990 | A |
4929447 | Yang | May 1990 | A |
4929508 | Sharma et al. | May 1990 | A |
4933184 | Tsuk | Jun 1990 | A |
4935242 | Sharma et al. | Jun 1990 | A |
4938963 | Parnell | Jul 1990 | A |
4944949 | Story et al. | Jul 1990 | A |
4963367 | Ecanow | Oct 1990 | A |
4963369 | Song et al. | Oct 1990 | A |
4968511 | D'Amelia et al. | Nov 1990 | A |
4968716 | Markham | Nov 1990 | A |
4971079 | Talapin et al. | Nov 1990 | A |
4971787 | Cherukuri et al. | Nov 1990 | A |
4971806 | Cherukuri et al. | Nov 1990 | A |
4975270 | Kehoe | Dec 1990 | A |
4975288 | Hager et al. | Dec 1990 | A |
4978537 | Song | Dec 1990 | A |
4980178 | Cherukuri et al. | Dec 1990 | A |
4997654 | Corsello et al. | Mar 1991 | A |
4997659 | Yatka et al. | Mar 1991 | A |
5013716 | Cherukuri et al. | May 1991 | A |
5015464 | Strobridge | May 1991 | A |
5045325 | Lesko et al. | Sep 1991 | A |
5070085 | Markham | Dec 1991 | A |
5077051 | Gallopo et al. | Dec 1991 | A |
5078460 | Holsinger | Jan 1992 | A |
5087460 | Cherukuri et al. | Feb 1992 | A |
5110608 | Cherukuri et al. | May 1992 | A |
5124156 | Shibata et al. | Jun 1992 | A |
5125819 | Hager et al. | Jun 1992 | A |
5126151 | Bodor et al. | Jun 1992 | A |
RE33988 | Evans | Jul 1992 | E |
5139787 | Broderick et al. | Aug 1992 | A |
5139794 | Patel et al. | Aug 1992 | A |
5154927 | Song et al. | Oct 1992 | A |
5156842 | Mulligan | Oct 1992 | A |
5179122 | Greene et al. | Jan 1993 | A |
5182099 | Jonsson et al. | Jan 1993 | A |
5229137 | Wolfe | Jul 1993 | A |
5244670 | Upson et al. | Sep 1993 | A |
5248508 | Reed et al. | Sep 1993 | A |
5284657 | Lu et al. | Feb 1994 | A |
5286500 | Synosky et al. | Feb 1994 | A |
5294433 | Singer et al. | Mar 1994 | A |
5294449 | Greenberg | Mar 1994 | A |
5324530 | Kehoe et al. | Jun 1994 | A |
5340566 | Curtis et al. | Aug 1994 | A |
5344659 | Kurihara et al. | Sep 1994 | A |
5378131 | Greenberg | Jan 1995 | A |
5380530 | Hill | Jan 1995 | A |
5380535 | Geyer et al. | Jan 1995 | A |
5397580 | Song et al. | Mar 1995 | A |
5409905 | Eby, III | Apr 1995 | A |
5410028 | Asami et al. | Apr 1995 | A |
5419919 | Song et al. | May 1995 | A |
5425961 | Yatka et al. | Jun 1995 | A |
5431929 | Yatka et al. | Jul 1995 | A |
5433960 | Meyers | Jul 1995 | A |
5445834 | Burger et al. | Aug 1995 | A |
5455286 | Amidon et al. | Oct 1995 | A |
5456677 | Spector | Oct 1995 | A |
5474989 | Hashimoto et al. | Dec 1995 | A |
5487902 | Andersen et al. | Jan 1996 | A |
5488962 | Perfetti | Feb 1996 | A |
5494685 | Tyrpin et al. | Feb 1996 | A |
5496541 | Cutler | Mar 1996 | A |
5498429 | Orlandi | Mar 1996 | A |
5512306 | Carlsson et al. | Apr 1996 | A |
5523097 | Song et al. | Jun 1996 | A |
5534272 | Bernstein | Jul 1996 | A |
5536511 | Yatka | Jul 1996 | A |
5543160 | Song et al. | Aug 1996 | A |
5554380 | Cuca et al. | Sep 1996 | A |
5569477 | Nesbitt | Oct 1996 | A |
5571528 | Lee et al. | Nov 1996 | A |
5571543 | Song et al. | Nov 1996 | A |
5576344 | Sandler et al. | Nov 1996 | A |
5578336 | Monte | Nov 1996 | A |
5580590 | Hartman | Dec 1996 | A |
5582855 | Cherukuri et al. | Dec 1996 | A |
5585110 | Kalili et al. | Dec 1996 | A |
5593685 | Bye et al. | Jan 1997 | A |
5601858 | Mansukhani et al. | Feb 1997 | A |
5605698 | Ueno | Feb 1997 | A |
5607697 | Alkire et al. | Mar 1997 | A |
5618517 | Miskewitz | Apr 1997 | A |
5628986 | Sanker et al. | May 1997 | A |
5629013 | Upson et al. | May 1997 | A |
5629026 | Davis | May 1997 | A |
5629035 | Miskewitz | May 1997 | A |
5637313 | Chau et al. | Jun 1997 | A |
5645853 | Winston et al. | Jul 1997 | A |
5651987 | Fuisz | Jul 1997 | A |
5656652 | Davis | Aug 1997 | A |
5665386 | Benet et al. | Sep 1997 | A |
5665406 | Reed et al. | Sep 1997 | A |
5667802 | Grimberg | Sep 1997 | A |
5670163 | Cuca et al. | Sep 1997 | A |
5693334 | Miskewitz | Dec 1997 | A |
5698215 | Kalili et al. | Dec 1997 | A |
5702687 | Miskewitz | Dec 1997 | A |
5711961 | Reiner et al. | Jan 1998 | A |
5716928 | Benet et al. | Feb 1998 | A |
5736175 | Cea et al. | Apr 1998 | A |
5744164 | Chauffard et al. | Apr 1998 | A |
5747475 | Nordquist et al. | May 1998 | A |
5753255 | Chavkin et al. | May 1998 | A |
5756074 | Ascione et al. | May 1998 | A |
5798101 | Haveson | Aug 1998 | A |
5800847 | Song et al. | Sep 1998 | A |
5824291 | Howard | Oct 1998 | A |
5827526 | Dohnalek et al. | Oct 1998 | A |
5830883 | Block et al. | Nov 1998 | A |
5834002 | Athanikar | Nov 1998 | A |
5846557 | Eisenstadt et al. | Dec 1998 | A |
5846952 | Vournakis et al. | Dec 1998 | A |
5854267 | Berlin et al. | Dec 1998 | A |
5858383 | Precopio | Jan 1999 | A |
5858391 | Cuca et al. | Jan 1999 | A |
5858412 | Staniforth et al. | Jan 1999 | A |
5858413 | Jettka et al. | Jan 1999 | A |
5858423 | Yajima et al. | Jan 1999 | A |
5866179 | Testa | Feb 1999 | A |
5877173 | Olney et al. | Mar 1999 | A |
5880109 | Nakamura et al. | Mar 1999 | A |
5882702 | Abdel-Malik et al. | Mar 1999 | A |
5885630 | Zurawski et al. | Mar 1999 | A |
5885992 | Ohgi et al. | Mar 1999 | A |
5889028 | Sandborn et al. | Mar 1999 | A |
5889029 | Rolf | Mar 1999 | A |
5891422 | Pan et al. | Apr 1999 | A |
5897891 | Godfrey | Apr 1999 | A |
5900230 | Cutler | May 1999 | A |
5910308 | D'Jang | Jun 1999 | A |
5912007 | Pan et al. | Jun 1999 | A |
5912030 | Huzinec et al. | Jun 1999 | A |
5916606 | Record et al. | Jun 1999 | A |
5922346 | Hersh | Jul 1999 | A |
5922347 | Hausler et al. | Jul 1999 | A |
5928664 | Yang et al. | Jul 1999 | A |
5945107 | Hessel et al. | Aug 1999 | A |
5958380 | Winston et al. | Sep 1999 | A |
5958472 | Robinson et al. | Sep 1999 | A |
5980955 | Greenberg et al. | Nov 1999 | A |
5989588 | Korn et al. | Nov 1999 | A |
6024988 | Ream et al. | Feb 2000 | A |
6066342 | Gurol et al. | May 2000 | A |
6077524 | Bolder et al. | Jun 2000 | A |
6090412 | Hashimoto et al. | Jul 2000 | A |
6139872 | Walsh | Oct 2000 | A |
6165516 | Gudas et al. | Dec 2000 | A |
6200604 | Pather et al. | Mar 2001 | B1 |
6224872 | Shibuya et al. | May 2001 | B1 |
6242019 | Bell et al. | Jun 2001 | B1 |
6248378 | Ganan-Calvo | Jun 2001 | B1 |
6280762 | Bealin-Kelly et al. | Aug 2001 | B1 |
6290985 | Ream et al. | Sep 2001 | B2 |
6350480 | Urnezis et al. | Feb 2002 | B1 |
6491540 | Barreca | Dec 2002 | B1 |
6586023 | Song et al. | Jul 2003 | B1 |
6627234 | Johnson et al. | Sep 2003 | B1 |
6652839 | Barreca | Nov 2003 | B2 |
6773716 | Ream et al. | Aug 2004 | B2 |
6869614 | Barreca | Mar 2005 | B2 |
6872410 | Soldani et al. | Mar 2005 | B2 |
6949264 | McGrew et al. | Sep 2005 | B1 |
7163705 | Johnson et al. | Jan 2007 | B2 |
7351425 | Barreca | Apr 2008 | B2 |
7612045 | Eldridge | Nov 2009 | B2 |
8202561 | Livaich | Jun 2012 | B2 |
8679522 | Barreca | Mar 2014 | B2 |
20020110581 | Ream et al. | Aug 2002 | A1 |
20020127189 | Myers et al. | Sep 2002 | A1 |
20020159956 | Ream et al. | Oct 2002 | A1 |
20030138518 | Kiefer et al. | Jul 2003 | A1 |
20040247669 | Gin et al. | Dec 2004 | A1 |
20050002992 | McCleary et al. | Jan 2005 | A1 |
20050048164 | Stahl | Mar 2005 | A1 |
20060062863 | Ghosal | Mar 2006 | A1 |
20070123448 | Kaplan et al. | May 2007 | A1 |
20090143279 | Mootha et al. | Jun 2009 | A1 |
20120177730 | Baron et al. | Jul 2012 | A1 |
20130095140 | Baron et al. | Apr 2013 | A1 |
20130115329 | Savant et al. | May 2013 | A1 |
20130177604 | Baron et al. | Jul 2013 | A1 |
20140030332 | Baron et al. | Jan 2014 | A1 |
Number | Date | Country |
---|---|---|
WO 9818339 | May 1998 | WO |
WO 9823165 | Jun 1998 | WO |
WO 0006127 | Feb 2000 | WO |
WO 2014022772 | Feb 2014 | WO |
Entry |
---|
U.S. Appl. No. 14/220,224, filed Mar. 20, 2014, Barreca. |
The Food Channel newsletter, Aug. 30, 1996, vol. 8, No. 16. |
The Sydney Morning Herald, “Smarter up your act,” Sep. 11, 1999, 4 pages. |
On-line Medical Dictionary definition of “taurine”, Published at the Dept. of Medical Oncology, University of Newcastle upon Tyne, Copyright 1997-2004—The CancerWEB Project. Retrieved from: http://cancerweb.ncl.ac.uk/cgi-bin/omd?taurine. |
“Guaraná,” Tropical Plant Database, Raintree Nutrition, Inc., 1996-2003, (preprinted from Herbal Secrets of the Rainforest, 2nd edition, by Leslie Taylor, Sage Press, Inc., 2003). Retrieved from: http//www.rain.tree.com/guarana.htm. |
Arellano, “More Amore? Herbal Gum Makers Cater to Natural Urges”, Detroit Free Press, Mar. 29, 1994. |
Chaplin, “Water Activity,” updated Dec. 21, 2003, 4 pages. Retrieved from: www1.lsbu.ac.uk/water/. |
Harrison et al., “Ginseng,” Alternative Field Crops Manual, 1992, (updated Jan. 26, 2000), 8 pages. |
Horovitz, “Sticky business Ptooie! Gum on the outs with U.S. chewers”, USA Today, Jul. 16, 1998. |
Miura et al. “Effect of guarana on exercise in normal and epinephrine-induced glycogenolytic mice”; Biol PHarm Bull, Jun. 1998 21(6)646-8. |
Morton JF. “Widespread tannin intake via stimulants and masticatories, especially guarana, kola nut, betel vine, and accessorires”; Basic Life Sci 1992; 59:739-65. |
Sato et al., “On Drowsiness Preventive Gum that Contains Guarana Extract”, 1988, pp. 1-11. |
Sloan, Elizabeth A., “The Ten Top Functional Food Trends”, Food Technology, vol. 54, No. 4, Apr. 2000. |
Printout of Herbalife “NRG” Gum (known as “Chew Slim Gum”, 1992, 4 pages. |
Doyle et al., “Systems-based Disclovery of Tomatidine as a Natural Small Molecule Inhibitor of Skeletal Muscle Atrophy,” J. Biol. Chem., 2014, vol. 289(21), pp. 1491-1424. |
Number | Date | Country | |
---|---|---|---|
20140294915 A1 | Oct 2014 | US |
Number | Date | Country | |
---|---|---|---|
60154972 | Sep 1999 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11084707 | Mar 2005 | US |
Child | 12052054 | US | |
Parent | 10646503 | Aug 2003 | US |
Child | 11084707 | US | |
Parent | 10316700 | Dec 2002 | US |
Child | 10646503 | US | |
Parent | 09664630 | Sep 2000 | US |
Child | 10316700 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 14220224 | Mar 2014 | US |
Child | 14283459 | US | |
Parent | 12052054 | Mar 2008 | US |
Child | 14220224 | US |